Semnur Pharmaceuticals, Inc.

Denali Capital Acquisition Corp. (Nasdaq: DECA), sponsored by Denali Capital, is a blank-check company that targeted the consumer sector. The SPAC announced its proposed business combination with Semnur Pharmaceuticals, Inc. on August 22, 2025, and the transaction has since closed, concluding DECA's lifecycle as a publicly traded special purpose acquisition company. Denali Capital stewarded the vehicle through its deal process from announcement to completion, marking the end of the SPAC's active merger search. For full filing history, deal timelines, and analytics on DECA and hundreds of other SPACs, sign up for complete access at SpacDesk.

SPAC Counterparty (1)